annual cash & cash equivalents:
$344.07M-$15.22M(-4.24%)Summary
- As of today (June 22, 2025), TXG annual cash & cash equivalents is $344.07 million, with the most recent change of -$15.22 million (-4.24%) on December 31, 2024.
- During the last 3 years, TXG annual cash & cash equivalents has fallen by -$243.38 million (-41.43%).
- TXG annual cash & cash equivalents is now -48.15% below its all-time high of $663.60 million, reached on December 31, 2020.
Performance
TXG Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$377.06M+$32.99M(+9.59%)Summary
- As of today (June 22, 2025), TXG quarterly cash & cash equivalents is $377.06 million, with the most recent change of +$32.99 million (+9.59%) on March 31, 2025.
- Over the past year, TXG quarterly cash & cash equivalents has increased by +$21.28 million (+5.98%).
- TXG quarterly cash & cash equivalents is now -50.95% below its all-time high of $768.77 million, reached on September 30, 2020.
Performance
TXG quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TXG Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -4.2% | +6.0% |
| 3 y3 years | -41.4% | +20.7% |
| 5 y5 years | -18.9% | +1.2% |
TXG Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -41.4% | +56.6% | -5.3% | +71.6% |
| 5 y | 5-year | -48.1% | +56.6% | -51.0% | +71.6% |
| alltime | all time | -48.1% | +619.0% | -51.0% | +706.2% |
TXG Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $377.06M(+9.6%) |
| Dec 2024 | $344.07M(-4.2%) | $344.07M(-13.6%) |
| Sep 2024 | - | $398.16M(+4.8%) |
| Jun 2024 | - | $379.82M(+6.8%) |
| Mar 2024 | - | $355.78M(-1.0%) |
| Dec 2023 | $359.28M(+63.5%) | $359.28M(+15.4%) |
| Sep 2023 | - | $311.26M(-4.5%) |
| Jun 2023 | - | $325.88M(-1.9%) |
| Mar 2023 | - | $332.32M(+51.2%) |
| Dec 2022 | $219.75M(-62.6%) | $219.75M(-6.1%) |
| Sep 2022 | - | $233.95M(-14.7%) |
| Jun 2022 | - | $274.19M(-12.3%) |
| Mar 2022 | - | $312.49M(-46.8%) |
| Dec 2021 | $587.45M(-11.5%) | $587.45M(-2.2%) |
| Sep 2021 | - | $600.44M(-3.5%) |
| Jun 2021 | - | $621.96M(+0.8%) |
| Mar 2021 | - | $617.20M(-7.0%) |
| Dec 2020 | $663.60M | $663.60M(-13.7%) |
| Sep 2020 | - | $768.77M(+126.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $339.84M(-8.8%) |
| Mar 2020 | - | $372.43M(-12.2%) |
| Dec 2019 | $424.17M(+551.8%) | $424.17M(-0.8%) |
| Sep 2019 | - | $427.44M(+662.8%) |
| Jun 2019 | - | $56.03M(-13.9%) |
| Dec 2018 | $65.08M(+36.0%) | $65.08M(-88.1%) |
| Dec 2017 | $47.86M | - |
| Sep 2017 | - | $546.40M(+862.7%) |
| Jun 2017 | - | $56.76M(-2.5%) |
| Mar 2017 | - | $58.23M(+0.9%) |
| Dec 2016 | - | $57.70M(-15.2%) |
| Sep 2016 | - | $68.07M(-36.0%) |
| Jun 2016 | - | $106.35M(+11.3%) |
| Mar 2016 | - | $95.58M(+104.4%) |
| Dec 2015 | - | $46.77M(-84.2%) |
| Sep 2015 | - | $296.37M(+21.0%) |
| Jun 2015 | - | $244.93M(-2.1%) |
| Mar 2015 | - | $250.13M(-33.0%) |
| Dec 2014 | - | $373.14M |
FAQ
- What is 10x Genomics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for 10x Genomics?
- What is 10x Genomics annual cash & cash equivalents year-on-year change?
- What is 10x Genomics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for 10x Genomics?
- What is 10x Genomics quarterly cash & cash equivalents year-on-year change?
What is 10x Genomics annual cash & cash equivalents?
The current annual cash & cash equivalents of TXG is $344.07M
What is the all time high annual cash & cash equivalents for 10x Genomics?
10x Genomics all-time high annual cash & cash equivalents is $663.60M
What is 10x Genomics annual cash & cash equivalents year-on-year change?
Over the past year, TXG annual cash & cash equivalents has changed by -$15.22M (-4.24%)
What is 10x Genomics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of TXG is $377.06M
What is the all time high quarterly cash & cash equivalents for 10x Genomics?
10x Genomics all-time high quarterly cash & cash equivalents is $768.77M
What is 10x Genomics quarterly cash & cash equivalents year-on-year change?
Over the past year, TXG quarterly cash & cash equivalents has changed by +$21.28M (+5.98%)